The Know ALL website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so they may not be exact or complete; Know ALL cannot guarantee the accuracy of translated content. Know ALL and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help. The interviews webpage also uses YouTube, where subtitles and translations are generated automatically by AI; please be advised to exercise caution when precise interpretation is required. For further support with YouTube, visit YouTube Help.
Collaborating to manage immunotherapy side effects: Patient and HCP perspectives
Mark Litzow
August 12, 2025
This educational resource is independently supported by Amgen. All content was developed by SES in collaboration with an expert ambassador group. Funders were allowed no influence on the content of this resource.
During the recent Know ALL Ambassador Meeting, Dr Mark Litzow and Jess Olson, a Know ALL ambassador and patient, led a discussion on how healthcare professionals and patients can collaborate to manage side effects associated with immunotherapy in acute lymphoblastic leukemia (ALL).
During the discussion, Dr Litzow explained how immunotherapy is being used to treat ALL by helping the body’s immune system find and kill leukemia cells. Dr Litzow also addressed common side effects of immunotherapy and described how these are managed by healthcare providers. Jess Olson shared their personal experience with blinatumomab, a type of immunotherapy, and what helped manage those side effects. Dr Litzow and Jess discussed how healthcare providers and patients can work together to improve communication, personalize care, and address barriers to accessing immunotherapy – ensuring that treatment focuses on both treating ALL and improving quality of life.
